Form 8-K - Current report:
SEC Accession No. 0001847367-25-000010
Filing Date
2025-03-19
Accepted
2025-03-19 16:12:18
Documents
15
Period of Report
2025-03-19
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tmb-20250319x8k.htm   iXBRL 8-K 32877
2 EX-99.1 tmb-20250319xex99d1.htm EX-99.1 148104
3 GRAPHIC tmb-20250319xex99d1001.jpg GRAPHIC 4353
  Complete submission text file 0001847367-25-000010.txt   324582

Data Files

Seq Description Document Type Size
4 EX-101.SCH tmb-20250319.xsd EX-101.SCH 3259
5 EX-101.LAB tmb-20250319_lab.xml EX-101.LAB 15917
6 EX-101.PRE tmb-20250319_pre.xml EX-101.PRE 10316
17 EXTRACTED XBRL INSTANCE DOCUMENT tmb-20250319x8k_htm.xml XML 4849
Mailing Address 280 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 280 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 650-231-6625
ALUMIS INC. (Filer) CIK: 0001847367 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42143 | Film No.: 25752876
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)